Menu Search
Equities

Humanigen Inc

0KB2:STU

Humanigen Inc

Actions
  • Price (EUR)0.0134
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-90.76%
  • Beta--
Data delayed at least 15 minutes, as of Sep 07 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Humanigen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Its product candidate, lenzilumab, and its other product candidate, ifabotuzumab (iFab), are Humaneered monoclonal antibodies are Humaneered monoclonal antibodies. lenzilumab is used as a therapeutic for chronic myelomonocytic leukemia; for the prevention of acute graft versus host disease; and as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T) programs. The Company has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them.

  • Revenue in USD (TTM)1.70m
  • Net income in USD-53.63m
  • Incorporated2001
  • Employees6.00
  • Location
    Humanigen Inc830 MORRIS TURNPIKE, 4TH FLOORSHORT HILLS 07078United StatesUSA
  • Phone+1 (973) 200-3100
  • Fax+1 (302) 531-3150
  • Websitehttps://www.humanigen.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.